{"product_id":"flgt-bcg-matrix","title":"(FLGT) Fulgent Genetics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Fulgent Genetics, Inc. BCG Matrix helps you see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. This page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.’s oncology panels sit in a Star role because they target cancer identification in a precision oncology market that keeps expanding. The company offers broad, clinically used panel testing, so demand can recur as patients move through diagnosis, treatment selection, and monitoring. In 2025, precision oncology adoption stayed strong across U.S. labs and health systems, supporting volume growth for panel-based testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolid tumor molecular profiling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSolid tumor molecular profiling is a core Fulgent Genetics cancer test and fits a Stars slot because oncology keeps shifting toward biomarker-driven care. Fulgent Genetics reported 2024 revenue of about $286 million, while the broader molecular diagnostics market is still growing at double-digit rates, supporting demand. As more solid-tumor cases need faster, deeper gene panels, this line stays high-need and high-growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid whole genome testing for NICU and PICU\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.'s rapid whole genome testing for NICU and PICU is a Star because it targets critically ill newborns and children where hours matter. Published NICU\/PICU studies show diagnostic yields around 30% to 50%, and turnaround times can be under 48 hours, making the test both clinically high value and time-sensitive. As sequencing gets faster and more embedded in care, this category should keep expanding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBeacon carrier screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBeacon carrier screening targets inherited conditions and fits a broad reproductive genetics market that keeps expanding as preconception and prenatal testing rise. For Fulgent Genetics, Inc., the offer has scale potential because it can be sold through OB-GYN, fertility, and health system channels, with repeat use tied to family planning. In BCG terms, that mix of market growth and channel breadth supports a Star profile if share keeps rising.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInherited-condition testing\u003c\/li\u003e\n\u003cli\u003eBroad reproductive demand\u003c\/li\u003e\n\u003cli\u003eMulti-channel scale potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eComprehensive exome and whole genome testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent Genetics’ exome and whole genome tests are a Star because they fit rare-disease and hard-to-diagnose cases, where broader sequencing can find variants single-gene panels miss. Global demand keeps rising as sequencing costs fall and more clinicians use genomic testing in routine care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBest fit for rare and complex cases\u003c\/li\u003e\n\u003cli\u003eBroader reach than fixed panels\u003c\/li\u003e\n\u003cli\u003eDemand grows with lower sequencing costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese tests also support recurring clinical use, so adoption can expand as payer coverage and physician comfort improve.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent’s Growth Stars: Oncology and Rapid NICU Sequencing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.'s Stars are oncology panels, rapid NICU\/PICU sequencing, carrier screening, and exome\/whole genome tests because each ties to a growing clinical need and can scale with more testing use. Fulgent Genetics, Inc. reported about $286 million in 2024 revenue, while NICU\/PICU sequencing studies show 30% to 50% diagnostic yields and under-48-hour turnaround.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar area\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology panels\u003c\/td\u003e\n\u003ctd\u003eHigh-growth precision oncology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNICU\/PICU WGS\u003c\/td\u003e\n\u003ctd\u003e30%–50% yield; \u0026lt;48h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eFulgent Genetics BCG Matrix: maps its testing and sequencing businesses to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Fulgent Genetics BCG Matrix for fast portfolio clarity and strategy decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eShows the source trail behind Fulgent Genetics, Inc. data, boosting credibility and making investment decisions easier to verify.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlow cytometry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFlow cytometry is a mature lab service for cell analysis and malignancy monitoring, so it fits a Cash Cow in Fulgent Genetics, Inc.'s BCG Matrix. It supports steady repeat demand from oncology follow-up and routine diagnostics, which usually means stable utilization and dependable cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFISH testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFISH testing is a mature fluorescence in situ hybridization method used to spot specific DNA sequences in cancer, prenatal, and rare-disease workflows. Its long clinical track record and routine lab use support steady demand, which fits a Cash Cow role in Fulgent Genetics, Inc.'s BCG Matrix. In a stable segment like this, the main value is dependable cash generation rather than high growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunohistochemistry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunohistochemistry is a mature cash cow for Fulgent Genetics, Inc., used to visualize cellular antigens in pathology and oncology. In 2025, it stayed standard in tumor workups because it is fast, repeatable, and operationally efficient. That makes it a steady-margin service with limited reinvestment needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCytogenetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCytogenetics is Fulgent Genetics, Inc.’s core chromosomal analysis service, used in established lab workflows to detect chromosomal anomalies. It fits the Cash Cows quadrant because demand is steady, the test menu is mature, and growth is usually modest but dependable.\u003c\/p\u003e\n\u003cp\u003eIts value is in routine volume and clinical necessity, not rapid expansion. In 2025, Fulgent Genetics reported full-year revenue of about $300 million, and the stable testing base helped support recurring diagnostics income across core services.\u003c\/p\u003e\n\u003cp\u003eFor BCG analysis, Cytogenetics acts as a low-growth, high-reliability asset: it keeps utilization up, supports physician and hospital relationships, and anchors revenue in a proven workflow. That makes it a dependable cash generator rather than a growth driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore chromosomal anomaly testing\u003c\/li\u003e\n\u003cli\u003eLow growth, steady clinical demand\u003c\/li\u003e\n\u003cli\u003eSupports recurring diagnostics revenue\u003c\/li\u003e\n\u003cli\u003eBest viewed as a cash generator\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHematopoietic and solid tumor molecular testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.’s hematopoietic and solid tumor molecular testing fits Cash Cows: it feeds repeat hospital and lab workflows, so revenue comes from steady case volume, not big new installs. In 2025, the segment sat in a mature lab-services market while the company kept focusing on margin discipline and utilization, which matters more than fast top-line growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring, protocol-based testing\u003c\/li\u003e\n\u003cli\u003eHospital and lab reorder demand\u003c\/li\u003e\n\u003cli\u003eVolume-led, margin-sensitive economics\u003c\/li\u003e\n\u003cli\u003eLow growth, steady cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent Genetics’ Steady Cash Cows Anchor ~$300M in 2025 Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.’s Cash Cows are mature lab services like cytogenetics, FISH, IHC, and flow cytometry, where demand is steady and reinvestment needs are low. In 2025, Fulgent Genetics reported about $300 million in full-year revenue, showing the value of its stable testing base. These services matter more for reliable cash flow than fast growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-year revenue\u003c\/td\u003e\n\u003ctd\u003e~$300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Cow tests\u003c\/td\u003e\n\u003ctd\u003eMature core services\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth profile\u003c\/td\u003e\n\u003ctd\u003eLow to modest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eFulgent Genetics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis Fulgent Genetics, Inc. BCG Matrix preview is the exact document you’ll receive after purchase. No placeholders or hidden changes—just the same professionally formatted file shown here. Once purchased, it’s ready for immediate download, use, and sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSARS-CoV-2 RT-PCR testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSARS-CoV-2 RT-PCR testing was a major COVID-19 revenue driver for Fulgent Genetics, Inc., but demand has collapsed from pandemic peaks as routine screening faded. In 2024, the company’s revenue was far below 2021 highs, showing this line is now a low-growth legacy business. In a BCG Matrix, it fits \"Dog\": weak growth and limited strategic pull.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSARS-CoV-2 antigen testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSARS-CoV-2 antigen testing is a Dogs business for Fulgent Genetics, Inc. because demand has fallen with pandemic normalization, and pricing is under heavy pressure. The U.S. COVID-19 public health emergency ended on May 11, 2023, and this product line now competes in a much smaller, lower-margin market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSARS-CoV-2 next-generation sequencing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSARS-CoV-2 next-generation sequencing is a narrow \"Dog\" for Fulgent Genetics, Inc., because it serves one pathogen and a limited research-heavy use case. Pandemic demand peaked in 2020-2021, and by 2025 this category had far less volume and weaker growth than broad hereditary testing. With COVID-19 testing and surveillance normalizing, long-term upside looks limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSARS-CoV-2 diagnostic franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.’s SARS-CoV-2 diagnostic franchise used PCR, antigen, and other formats, and it was a key revenue driver in earlier pandemic quarters. With COVID demand normalized, the line is now structurally lower growth and likely a Dogs-style asset in the BCG Matrix. Recent filings show the franchise has shrunk to a small part of sales, while Fulgent’s core 2025–2026 focus shifted back to oncology and inherited disease testing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly pandemic: material revenue contributor\u003c\/li\u003e\n\u003cli\u003eNow: low-growth, low-priority segment\u003c\/li\u003e\n\u003cli\u003eMultiple test formats, but demand faded\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePicture Genetics direct-to-patient testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePicture Genetics is Fulgent Genetics, Inc.’s patient-initiated testing brand, but consumer genetics is crowded, price-driven, and hard to scale. In FY2025 terms, that weak market position and limited share fit a BCG Dog: low growth, low share, and weak capital efficiency. The asset looks more like an option than a core engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow share in a crowded market\u003c\/li\u003e\n\u003cli\u003eWeak scale economics\u003c\/li\u003e\n\u003cli\u003eBest kept lean\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent’s COVID Testing Franchises: A Shrinking Dog\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.’s COVID testing franchise is now a Dog: demand fell sharply after the May 11, 2023 public health emergency ended, and FY2025 sales were far below pandemic peaks. With PCR, antigen, and sequencing tied to a shrinking market, the segment has weak growth, low share, and little capital pull.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDogs view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID testing demand\u003c\/td\u003e\n\u003ctd\u003eDown since 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 role\u003c\/td\u003e\n\u003ctd\u003eLow-priority\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHelio blood-based early cancer detection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent’s Helio Health partnership keeps blood-based early cancer detection in a high-growth question mark: the global liquid biopsy market was about $7.5 billion in 2025 and is still expanding fast. Commercial share is still being built, so revenue is likely early-stage, but the long-term market is large. For BCG, this is a Question Mark with strong upside, but it still needs adoption and reimbursement wins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNewborn genetic analysis panel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNewborn genetic analysis panel sits in the Question Mark zone: clinically important, but adoption still depends on workflow fit and lab validation. Fulgent Genetics, Inc. reported $289.0 million in 2025 revenue, yet it did not break out this panel’s sales, so the category’s scale is still unclear. The market has real growth potential, but hospital integration and reimbursement will decide how fast it scales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFront-line test for ataxia-related variants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics' front-line ataxia-related variant test is a narrow, single-indication offer, so it fits a Question Mark: low share now, but upside if neurologists adopt it. In Fulgent Genetics' latest filed FY2024 report, revenue was $320.5 million, and the hereditary disease mix was still small, so this niche has not yet reached scale. The commercial runway still depends on referral growth, payer coverage, and whether ataxia panels move into first-line use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMutation and repeat expansion testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMutation and repeat expansion testing fits Fulgent Genetics, Inc.'s question-mark bucket because it serves narrow inherited and neurologic niches, where precision medicine is lifting demand. Still, these assays compete against broader multi-panel menus from larger labs, so share is hard to pin down. The upside is real, but adoption and scale remain the key test.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh clinical need, narrow use case\u003c\/li\u003e\n\u003cli\u003ePrecision medicine can support growth\u003c\/li\u003e\n\u003cli\u003eShare pressure from larger panels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eResearch service tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.'s research service tests stay in question-mark territory: demand can grow, but the field is still crowded, fragmented, and price-sensitive.\u003c\/p\u003e\n\u003cp\u003eThat means the line can scale if Fulgent wins more biotech and pharma work, but it needs steady investment in sales, lab capacity, and turnaround speed to gain share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth potential: real, but uneven\u003c\/li\u003e\n\u003cli\u003eCompetition: high and fragmented\u003c\/li\u003e\n\u003cli\u003ePosition: still a question mark\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent’s Growth Questions: Big Market, Small Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.’s question marks still need share gains: Helio Health sits in a liquid biopsy market near $7.5 billion in 2025, while Fulgent Genetics, Inc. booked $289.0 million revenue in 2025. Newborn, ataxia, and repeat-expansion tests are clinically useful, but sales are still too small or unbroken out to show scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003cth\u003eBCG view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHelio Health\u003c\/td\u003e\n\u003ctd\u003e$7.5B market\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFulgent Genetics, Inc.\u003c\/td\u003e\n\u003ctd\u003e$289.0M revenue\u003c\/td\u003e\n\u003ctd\u003eLow share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234424201481,"sku":"flgt-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/flgt-bcg-matrix.webp?v=1785718837","url":"https:\/\/dcfanalyst.com\/products\/flgt-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}